Why the study?
Does low-dose alpha/beta blockade with doxazosin and betaxolol improve blood pressure reduction compared to monotherapy with hydrochlorothiazide or quinapril in patients with essential hypertension?
Does low-dose alpha/beta blockade with doxazosin and betaxolol improve blood pressure reduction compared to monotherapy with hydrochlorothiazide or quinapril in patients with essential hypertension?
Low-dose alpha/beta blockade with doxazosin and betaxolol provides superior blood pressure reduction and target achievement compared to monotherapy with an ACE inhibitor or a diuretic in essential hypertension.
Answers are grounded in this paper and cite their sources.
May support greater BP reduction with low-dose alpha/beta blockade; leaves open confirmation in randomized outcome trials.
Despite the recent emphasis on combination drug therapy for hypertension, little attention has been given to alpha/beta blockade using agents other than labetalol. The purpose of this study was to 1) compare the efficacy of low-dose alpha/beta blockade using doxazosin + betaxolol, versus monotherapy with an angiotensin converting enzyme inhibitor (quinapril) and a diuretic (hydrochlorothiazide [HCTZ]), and 2) assess the efficacy of low-dose doxazosin. In a crossover study, 21 hypertensive subjects were treated for 3 weeks each with HCTZ, 12.5 to 25 mg/day, quinapril, 10 to 40 mg/day, and a combination of doxazosin, 1 to 4 mg + betaxolol, 5 to 10 mg daily. Doses were titrated to achieve a systolic pressure <130 mm Hg, as assessed by self-recorded home measurements. Home blood pressure decreased 11.5/7.5 mm Hg after HCTZ, 12.9/8.8 mm Hg after quinapril, and 21.2/16.5 mm Hg after doxazosin + betaxolol (P < .001/< .001 v HCTZ and P < .002/< .001 v quinapril). The target systolic pressure was achieved by 33%, 43%, and 71% of subjects, respectively (P = .04 v HCTZ, and .03 v quinapril). Among the 8 subjects in whom doxazosin dosage was increased to the maximum of 4 mg, the mean blood pressure achieved at 4 mg did not differ from that achieved at 2 mg (136/87 v 136/88 mm Hg). We conclude that oral alpha/beta blockade is superior to monotherapy with an angiotensin converting enzyme inhibitor or a diuretic and that maximal or near maximal efficacy can be achieved at a 2-mg dose of doxazosin. Low-dose oral alpha/beta blockade merits greater consideration in the drug therapy of essential hypertension.
No takes yet. Share an insight, caveat, or question.
Samuel J. Mann (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: